{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "KRW", "esgPopulated": false, "market": "kr_market", "longName": "EyeGene Inc.", "marketState": "PREPRE", "regularMarketPrice": 4380.0, "exchange": "KOE", "shortName": "Eyegene", "exchangeTimezoneShortName": "KST", "exchangeTimezoneName": "Asia/Seoul", "regularMarketChangePercent": -1.1286682, "gmtOffSetMilliseconds": 32400000, "fiftyTwoWeekLowChange": 150.0, "fiftyTwoWeekLowChangePercent": 0.035460994, "fiftyTwoWeekRange": "4230.0 - 12500.0", "fiftyTwoWeekHighChange": -8120.0, "fiftyTwoWeekHighChangePercent": -0.6496, "fiftyTwoWeekLow": 4230.0, "fiftyTwoWeekHigh": 12500.0, "firstTradeDateMilliseconds": 1447632000000, "priceHint": 2, "regularMarketChange": -50.0, "regularMarketTime": 1683873030, "regularMarketDayHigh": 4545.0, "regularMarketDayRange": "4370.0 - 4545.0", "regularMarketDayLow": 4370.0, "regularMarketVolume": 51772, "regularMarketPreviousClose": 4430.0, "bid": 4055.0, "ask": 4410.0, "fullExchangeName": "KOSDAQ", "financialCurrency": "KRW", "regularMarketOpen": 4450.0, "averageDailyVolume3Month": 127457, "averageDailyVolume10Day": 70714, "sharesOutstanding": 10993100, "fiftyDayAverage": 4703.0, "fiftyDayAverageChange": -323.0, "fiftyDayAverageChangePercent": -0.06867956, "twoHundredDayAverage": 6417.15, "twoHundredDayAverageChange": -2037.1499, "twoHundredDayAverageChangePercent": -0.317454, "marketCap": 48149778432, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "symbol": "185490.KQ"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "B-910, 401, Yangcheon-ro", "address2": "Gangseo-gu", "city": "Seoul", "zip": "07528", "country": "South Korea", "phone": "82 2 322 1687", "fax": "82 2 302 4359", "website": "https://www.eyegene.co.kr", "industry": "", "sector": "", "longBusinessSummary": "EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, a Phase IIa clinical trial product candidate for the treatment of diabetic retinopathy; EG-Decorin, a Phase I/II clinical trial product for the treatment for pressure ulcers; EG-Myocin, a product that is in Phase II clinical trials for the treatment of heart muscle; and EG-HPV, a product that completed Phase I clinical trial for the treatment of cervical cancer. Its products in pipeline also include EG-TB for the treatment of tuberculosis; and EG-HZ, which is in preclinical trials for the treatment of herpes zoster. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Mr. Won-Il  Yoo", "title": "Chief Exec. Officer and Pres", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Yang-Je  Cho", "title": "Co-Founder and Chief Technology Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Soobeom  Lee", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}